Therapeutic Strategies for the Management of HCV/HIV co- infection

最近在治疗和监测艾滋病毒感染方面取得的进展大大降低了与艾滋病毒有关的发病率和死亡率；然而，艾滋病毒感染者的管理变得越来越复杂。我们正在进行研究，以(1)评估控制hiv合并感染者丙型肝炎病毒（HCV）感染的新治疗策略，以及(2)确定可以预测hiv感染者对现有HCV治疗和/或未来治疗反应的关键宿主因素。在过去的一年里，我们(1)确定了每月两次白蛋白-干扰素α 2b加利巴韦林治疗合并感染HIV的丙型肝炎患者的新方案的安全性、耐受性和有效性；(2)证明了持续的HIV复制对合并丙型肝炎患者的宿主免疫激活谱的明显影响；(3)证明了种族和基线免疫状态（CD4+ t细胞计数）对聚乙二醇化干扰素- α和利巴韦林治疗HCV的应答率的影响；(4)利用新开发的HCV连续培养系统在体外评估了新型抗HCV药物（IL-27、IL-28和IL-29）；(5)证明了干扰素诱导基因产物在体外控制HCV复制中的作用。

Recent advances in the treatment and monitoring of HIV infection have substantially reduced rates of HIV-associated illness and mortality; however, the management of HIV-infected patients has become increasingly complex. We are conducting studies to (1) evaluate novel therapeutic strategies for managing hepatitis C virus (HCV) infection in HIV-co-infected individuals, and (2) identify critical host factors that can predict an HIV-infected individuals response to existing HCV treatments and/or future therapies. This past year, we (1) determined the safety, tolerability and effectiveness of a novel regimen of twice monthly albumin-interferon alpha 2b plus ribavirin to treat Hepatitis C in HIV co-infected individuals; (2) demonstrated the distinct influence of ongoing HIV replication on host immune activation profiles in patients co-infected with Hepatitis C; (3) demonstrated the effect of race and baseline immune status (CD4+ T-cell count) on response rates to HCV therapy using pegylated interferon-alpha and ribavirin, (4) evaluated novel anti-HCV agents (IL-27, IL-28 and IL-29) in vitro using a newly developed HCV continuous culture system, and (5) demonstrated the role of individual Interferon-inducible gene products in controlling HCV replication in vitro.